Literature DB >> 15168081

An improved assay for enumeration of circulating endothelial cells.

A Woywodt1, C Goldberg, J Scheer, H Regelsberger, H Haller, M Haubitz.   

Abstract

Circulating endothelial cells have been established as markers of vascular disease, such as small vessel vasculitis, acute vascular rejection in renal transplant recipients, and cyclosporine-induced endothelial damage. Enumeration of these cells by immunomagnetic isolation and acridine staining remains the gold standard but necessitates considerable experience and expenditure. A simpler test would therefore be of great utility. Hence, our aim was to develop an improved simple assay to enumerate endothelial cells in peripheral blood. We had already used various surface markers to corroborate the endothelial origin of cells. Here, we studied the enumeration of cell numbers with immunomagnetic isolation and a variety of subsequent stains, such as CD31, von Willebrand's factor (vWF) immunocytochemistry, and Ulex europaeus lectin-1 (UEA-1). Eventually, we devised a simple protocol for enumeration using immunomagnetic isolation and a subsequent UEA-1 lectin stain. We evaluated the use of this protocol in parallel to immunomagnetic isolation and acridine counting alone in 92 renal transplant recipients who underwent renal biopsy. Recovery of various concentrations of human umbilical vein endothelial cells from blood was also studied. Immunomagnetic isolation and subsequent UEA-1 staining permits easier enumeration of circulating endothelial cells in peripheral blood. The assay is simple and easy to use, thus allowing for a more widespread use of circulating endothelial cells as a marker of vascular damage. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168081     DOI: 10.1007/s00277-004-0878-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis.

Authors:  A Woywodt; C Goldberg; T Kirsch; K de Groot; U Erdbruegger; H Haller; M Haubitz
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

2.  Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood.

Authors:  Christopher J Boos; Deirdre A Lane; Delene Kang; Patrick K Y Goon; Andrew D Blann; Gregory Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

3.  Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor.

Authors:  V J Karthikeyan; Andrew D Blann; Sabah Baghdadi; Deirdre A Lane; D Gareth Beevers; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2011-01-09       Impact factor: 5.460

4.  Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.

Authors:  Fadi Najjar; Moosheer Alammar; Marroan Bachour; Nissreen Almalla; Moaz Altahan; Ali Alali; Ghassan Al-Massarani
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-19       Impact factor: 4.553

5.  Circulating endothelial cells as biomarker for cardiovascular diseases.

Authors:  Maura Farinacci; Thomas Krahn; Wilfried Dinh; Hans-Dieter Volk; Hans-Dirk Düngen; Josephine Wagner; Timo Konen; Oliver von Ahsen
Journal:  Res Pract Thromb Haemost       Date:  2018-10-26

6.  Circulating endothelial cells (CECs) and E-selectin: Predictors of preeclampsia.

Authors:  Ferdous Mehrabian; Sayed Mohammad Hashemi Jazi; Shaghayegh Haghjooy Javanmard; Mahshid Kaviani; Vida Homayouni
Journal:  J Res Med Sci       Date:  2012-01       Impact factor: 1.852

7.  Circulating Endothelial Cells as Promising Biomarkers in the Differential Diagnosis of Primary Angiitis of the Central Nervous System.

Authors:  Milani Deb-Chatterji; Hans Otto Pinnschmidt; Yinghui Duan; Vivien Haeussler; Björn Rissiek; Christian Gerloff; Götz Thomalla; Tim Magnus
Journal:  Front Neurol       Date:  2020-03-31       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.